CYTODYN INC. DL -,01 WKN: A0YHA5 ISIN: US23283M1018 Kürzel: 296 Forum: Aktien Thema: Hauptdiskussion

Dann drücken wir mal die Daumen dass das persönliche Treffen was bringt ✊🏻

CytoDyn Granted Small Business Waiver of Application Fees by FDA for Leronlimab (PRO 140) BLA Filing “We are extremely grateful to the FDA for granting the fee waiver,” stated CytoDyn President and CEO, Nader Pourhassan, Ph.D. “Our goal firmly remains to complete in September 2019 the BLA filing with the FDA for leronlimab as a combination therapy with HAART for HIV-infected patients and hopefully initiate our first monotherapy pivotal trial for label expansion soon after our in-person meeting with the FDA,” continued Dr. Pourhassan. “We are also hopeful to initiate our funded PrEP clinical trial this year, which will be conducted in Thailand.” https://www.cytodyn.com/newsroom/press-releases/detail/347/cytodyn-granted-small-business-waiver-of-application-fees

CytoDyn Sponsored Research Reaffirms the Role of CCR5 in Cancer Biology and Provides a New Potential Cancer Treatment Modality Exciting results from Daniel Lindner, M.D., Ph.D. at the Cleveland Clinic with leronlimab on human colon carcinoma https://www.globenewswire.com/news-release/2019/08/02/1896197/0/en/CytoDyn-Sponsored-Research-Reaffirms-the-Role-of-CCR5-in-Cancer-Biology-and-Provides-a-New-Potential-Cancer-Treatment-Modality.html

CytoDyn Executes Exclusive Worldwide Licensing Agreement with IncellDX for PA-14 and PRO 140 for Diagnostic Testing Purposes Agreement represents a revenue opportunity as a diagnostic test for receptor occupancy and the existence of CCR5 on cancer tissue and in HIV https://www.globenewswire.com/news-release/2019/07/26/1892175/0/en/CytoDyn-Executes-Exclusive-Worldwide-Licensing-Agreement-with-IncellDX-for-PA-14-and-PRO-140-for-Diagnostic-Testing-Purposes.html

Das klingt nach einem guten Verlauf und das es noch ein bisschen dauert, aber es bewegt sich was in die richtige Richtung 👍🏻 Danke Schorsch 👏🏻

CytoDyn Finalizes Development of Receptor Occupancy Test to Guide Pivotal Monotherapy Discussions With the FDA GlobeNewswireJuly 25, 2019, 12:00 PM GMT+2 -       FDA face-to-face meeting granted to discuss pivotal monotherapy trial -       Conference call for investors and media on Tuesday, July 30, 2019 at 4:00 p.m. ET with introduction to Dr. Jonah Sacha for CURE and PrEP programs, Dr. Bruce Patterson for CCR5 receptor occupancy for HIV and cancer, and Dr. Jacob Lalezari for TNBC trial https://finance.yahoo.com/news/cytodyn-finalizes-development-receptor-occupancy-100000939.html

TipTop, merci

👍Danke Schorsch

👍

CytoDyn Anticipates Revenue Commencing in August 2019 from Use of PA-14 and/or PRO 140 in Diagnostic Test GlobeNewswireJuly 1, 2019, 12:00 PM GMT+2 CytoDyn Signs Non-binding Agreement for Diagnostic License and Supply Agreement with IncellDX for PA-14 and/or  PRO 140 (non-commercial grade) Collaboration represents an immediate revenue opportunity as a diagnostic test for receptor occupancy and the existence of CCR5 on cancer tissue and in HIV “Our non-binding agreement with IncellDX, subject to execution of a definitive agreement, which is expected to be finalized in July 2019, may lead to our first ever product revenues,” stated CytoDyn President and CEO, Nader Pourhassan, Ph.D.  “Importantly, the PRO 140 used for the PA-14 diagnostic test is non-commercial grade product in storage.  As such, this transaction allows CytoDyn to potentially realize significant value from product that would have very likely been discarded,” continued Dr. Pourhassan.  “Each diagnostic test may use 20 micro mg (mcg) of PRO 140 (1 mg = 1,000 mcg), implying significant revenue opportunity for CytoDyn, since any use of leronlimab for commercial purposes will require this diagnostic test.  Bottom ***, this is a small first step in realizing full value from PRO 140,” concluded Dr. Pourhassan. https://finance.yahoo.com/news/cytodyn-anticipates-revenue-commencing-august-100000970.html?.tsrc=rss

👋👋👋